Sorrento achieves 100% discharge rate in COVI-MSC study in COVID-19

Apr. 20, 2021 9:20 AM ETSorrento Therapeutics, Inc. (SRNE)SRNEBy: Mamta Mayani, SA News Editor15 Comments
  • Sorrento Therapeutics (NASDAQ:SRNE) has completed enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS).
  • This current study (MSC-COV-101) is a single arm study of the safety and preliminary efficacy of COVI-MSCs administered every other day for up to three infusions for a total of 1 x 106 cells/kg, with patients being followed for 28 days following the final infusion.
  • A total of 10 patients were enrolled and all were discharged from the hospital to home within three days of their last COVI-MSC infusion.
  • The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.
  • Once the full dataset is available, Sorrento will be working with the FDA to plan a placebo-controlled study to support an emergency use authorization submission.
  • SRNE shares up 2.1% premarket trading at $7.65.

Recommended For You

Comments (15)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.